Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DT-168 · 1 trial · 2 indications
Assessment of DT-168 on splicing patterns in genes that are known to be disrupted in FECD.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Drug: DT-168 |
| Name | Type | Description |
|---|---|---|
| DT-168 | DRUG | Active |
Inclusion Criteria: * Participant is scheduled to undergo a keratoplasty for management of FECD independent of this study. * ≥30 years of age (inclusive). * Documented diagnosis of FECD in the study eligible eye. * Confirmation of positive TCF4 allele 18.1 CTG expansion in at least one allele. * Ca...
DT-168 is an investigational small molecule being developed for Fuchs Endothelial Corneal Dystrophy, a condition that affects the cornea and can lead to vision loss. It is currently in Phase 2 clinical development and is not yet approved by the FDA.
DT-168 is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DSGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Fuchs Endothelial Corneal Dystrophy.
DT-168 is in Phase 2 clinical development. It is currently being studied in a recruiting clinical trial for patients with Fuchs Endothelial Corneal Dystrophy. The drug is investigational and has not received FDA approval.
DT-168 is being evaluated in a Phase 2 clinical trial with the identifier NCT07024693, titled 'DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy.' The trial is recruiting participants in the United States and aims to enroll 28 patients aged 30 years and older.
The Phase 2 clinical trial of DT-168 is an uncontrolled, open-label study. It is not randomized and does not use a double-blind design, meaning all participants receive the study drug without a placebo control group.